Experimental investigations on increased resistance to infections with Candida albicans and Staphylococcus aureus Smith by 4-imino-1,4-diazobicyclo-(3.1.0)-hexane-2-on BM 06.002 (prop. INN imexon) in mice.
BM 06.002 increases the resistance of mice to experimentally induced chronic infection with Candida albicans. Furthermore, BM 06.002 leads to increased resistance in the case of experimentally induced infection with Staphylococcus aureus Smith, when a subtherapeutic dose of sulfadiazine is applied. In mice immunosuppressively pretreated with hydrocortisone, BM 06.002 effectuates immunorestauration.
D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006588:Hexanones / Q000627:therapeutic use*; D006854:Hydrocortisone / Q000494:pharmacology; D007109:Immunity; D007166:Immunosuppressive Agents; D007659:Ketones / Q000627:therapeutic use*; D051379:Mice; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000276:immunology*; D013411:Sulfadiazine / Q000627:therapeutic use
D001643:Bridged Bicyclo Compounds; D006588:Hexanones; D007166:Immunosuppressive Agents; D007659:Ketones; D013411:Sulfadiazine; D006854:Hydrocortisone